PMID- 32078962
OWN - NLM
STAT- MEDLINE
DCOM- 20200324
LR  - 20200324
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 85
DP  - 2020 Apr
TI  - Toxicity management with combination chemotherapy and programmed death 
      1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
PG  - 101979
LID - S0305-7372(20)30017-7 [pii]
LID - 10.1016/j.ctrv.2020.101979 [doi]
AB  - PURPOSE: The combination of an anti-programmed death 1 (PD-1) or anti-programmed 
      death ligand 1 (PD-L1) monoclonal antibody with platinum-based chemotherapy can 
      improve outcomes for patients with advanced non-small-cell lung cancer (NSCLC) or 
      small-cell lung cancer (SCLC) compared with chemotherapy alone. For patients 
      receiving these new treatment regimens, it is important that toxicities be 
      managed effectively. A particular challenge can be determining the etiology of an 
      event, especially when there are overlapping symptoms that can be attributed to 
      either immunotherapy or to platinum-based chemotherapy. Here, we evaluate adverse 
      events (AEs) reported in clinical trials of combination therapy with an anti-PD-1 
      or anti-PD-L1 (anti-PD-[L]1) immunotherapy and chemotherapy to provide 
      information on toxicity management. METHODS: We performed a systematic review of 
      the literature focused on randomized controlled trials of anti-PD-(L)1 therapy 
      combined with platinum-based chemotherapy for advanced/metastatic NSCLC and SCLC. 
      RESULTS: Eleven reports from 9 randomized studies evaluating pembrolizumab, 
      nivolumab, and atezolizumab combined with platinum-based chemotherapy in patients 
      with advanced lung cancer were identified. Immune-mediated AEs and infusion 
      reactions occurred more commonly in patients who received anti-PD-(L)1 
      immunotherapy with platinum-based chemotherapy compared with chemotherapy alone; 
      however, there was no evidence of unexpected or unanticipated toxicity with these 
      combinations. CONCLUSION: Combinations of anti-PD-(L)1 immunotherapy with 
      platinum-based chemotherapy regimens improve outcomes for patients with NSCLC and 
      SCLC, and toxicity is generally manageable. Strategies for appropriate workup of 
      AEs to allow clinicians to make informed decisions regarding causality and 
      treatment modifications when appropriate are an important element of management 
      of patients receiving an anti-PD-(L)1 agent combined with platinum-based 
      chemotherapy.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Hoffner, Brianna
AU  - Hoffner B
AD  - University of Colorado, Aurora, CO, USA. Electronic address: 
      brianna.hoffner@ucdenver.edu.
FAU - Leighl, Natasha B
AU  - Leighl NB
AD  - Princess Margaret Cancer Centre, Toronto, ON, Canada.
FAU - Davies, Marianne
AU  - Davies M
AD  - Yale University & Yale Comprehensive Cancer Center, New Haven, CT, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
DEP - 20200204
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
RN  - 52CMI0WC3Y (atezolizumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/pathology
MH  - Disease-Free Survival
MH  - Drug-Related Side Effects and Adverse Reactions/drug therapy/*etiology
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Neoplasm Invasiveness/pathology
MH  - Neoplasm Staging
MH  - Nivolumab/therapeutic use
MH  - Prognosis
MH  - Programmed Cell Death 1 Receptor/administration & dosage/*antagonists & 
      inhibitors
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Atezolizumab
OT  - Nivolumab
OT  - Paclitaxel
OT  - Pembrolizumab
OT  - Pemetrexed
OT  - Platinum
EDAT- 2020/02/23 06:00
MHDA- 2020/03/25 06:00
CRDT- 2020/02/21 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2020/01/24 00:00 [revised]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/03/25 06:00 [medline]
PHST- 2020/02/21 06:00 [entrez]
AID - S0305-7372(20)30017-7 [pii]
AID - 10.1016/j.ctrv.2020.101979 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 
      Feb 4.